Dulaglutide: First global approval

Drugs

Volumn 74, Issue 17, 2014, Pages 2097-2103

  Sanford, Mark ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; GLIMEPIRIDE PLUS METFORMIN; INSULIN LISPRO; METFORMIN; METFORMIN PLUS PIOGLITAZONE; SITAGLIPTIN; TRIACYLGLYCEROL LIPASE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT FUSION PROTEINS;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSPEPSIA; ELIMINATION HALF-LIFE; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINUS TACHYCARDIA; STEADY STATE; STOMACH EMPTYING; VOMITING; AGONISTS; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922004065     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0320-7     Document Type: Article

References (13)

1. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287-96.
2. Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790-7.
3. Eli Lilly and Company. Trulicity: US prescribing information. 2014. http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 30 Sept 2014.
4. Eli Lilly. FDA approves Trulicity™ (dulaglutide), Lilly's once-weekly therapy for adults with type 2 diabetes [media release]. 18 Sept 2014. https://investor.lilly.com/releasedetail.cfm?ReleaseID=871658.
5. European Medicines Agency, Committee for Medicinal Products for Human Use. Trulicity (dulaglutide): summary of opinion (initial authorisation). 2014. http://www.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002825/WC500173650.pdf. Accessed 30 Sept 2014.
6. US Food and Drug Administration. FDA approves Trulicity to treat type 2 diabetes [media release]. 18 Sept 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm.
7. US National Institutes of Health. ClinicalTrials.gov. 2014. https://clinicaltrials.gov/. Accessed 2 Oct 2014.
8. Umpierrez G, Povedano ST, Manghi FP, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168-76.
9. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-58.
10. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014. doi: 10.1016/s0140-6736(14)60976-4.
11. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) [abstract no. 38]. Diabetologia. 2014;57(Suppl. 1):S22.
12. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159-67.
13. Jendle J, Blonde L, Rosenstock J, et al. Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4) [abstract no. 42]. Diabetologia. 2014;57(Suppl. 1):S23-4.